Patients with HIV receiving 3-drug ART with BIC/FTC/TAF exhibited low rates of viremia, particularly those with high treatment adherence.

The US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...

A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More pharmaceutical news is about Dupixent, GLP-1 results, and more.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...

Men, women, gay, straight – it really just kinds of expands the opportunity for prevention’ Source: Twice-a-year shot to prevent HIV could stop transmission — if people can get it – Zimbabwe News Now ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The U.S. Food and Drug Administration this week approved Gilead Sciences’ twice-a-year shot, lenacapvir, to prevent HIV, Gilead announced on Wednesday, June 18. It is the first and only long-acting ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.